Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
FEMALE
NCT07311083

Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy

Led by Kliniken Essen-Mitte · Updated on 2026-05-08

60

Participants Needed

1

Research Sites

73 weeks

Total Duration

On this page

Sponsors

K

Kliniken Essen-Mitte

Lead Sponsor

K

Karl and Veronica Carstens Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Triple-negative breast cancer (TNBC) is considered a tumor with a high risk of recurrence and metastasis and requires aggressive systemic therapy combining immunotherapy and chemotherapy. If the therapy leads to complete remission (pCR), this is prognostically beneficial for patients. Studies demonstrating the influence of the microbiome on the development of cancer and on the efficacy and toxicity of immunotherapy and chemotherapy underscore the potential of targeted nutritional interventions. Current data from microbiome research indicate that a high-fiber, gut-healthy diet modulates the microbiota in such a way that the response to and toxicity of immunotherapy and chemotherapy could be improved. The aim of this project is to translate these findings into clinical care. The study will investigate whether an online integrative oncology group training program with mind-body elements supports and is feasible for the implementation of a high-fiber diet in patients with TNBC undergoing neoadjuvant immunotherapy and chemotherapy. The program will be compared with a control group that receives a flyer with nutritional recommendations. If the feasibility of this complementary medicine approach can be demonstrated, a confirmatory study is planned to investigate the expected effect on the pathological complete remission of TNBC.

CONDITIONS

Official Title

Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy

Who Can Participate

Age: 18Years - 75Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female patients aged 18 to 75 years
  • Histologically confirmed diagnosis of non-metastatic triple-negative breast cancer (TNM stage I-III)
  • Planned neoadjuvant chemotherapy and immunotherapy
  • Willingness to participate and signed consent form
Not Eligible

You will not qualify if you...

  • Advanced stage of disease with metastases
  • Severe physical or psychopharmacologically treated psychiatric comorbidity preventing participation
  • Pregnancy
  • Participation in other clinical studies with behavioral, psychological, or complementary interventions
  • Diet incompatible with high-fiber diet, such as ketogenic diet
  • Drug and/or alcohol abuse
  • Inability to complete questionnaires independently
  • History of colectomy
  • Gastrointestinal stenosis
  • Fructose intolerance
  • Histamine intolerance
  • Gluten intolerance
  • Unwillingness to refrain from probiotics during study
  • Eating disorders
  • No laptop or camera available for online training

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Evang. Kliniken Essen-Mitte gGmbH

Essen, North Rhine-Westphalia, Germany, 45276

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here